Company: NCNA
Filing Date: 2025-03-20
Form Type: 20-F
Source: 0000950170-25-042709
Chunk: 117

Company: NuCana plc
Filing Date: 2025-03-20
Form: 20-F
Item: Item 4
Chunk 117
---
ab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
 In November 2024, we published initial data from the NuTide:303 trial in MedRxiv. Significant tumor volume reductions and prolonged PFS were observed, including a patient with urothelial bladder cancer who achieved 100% reduction in their target lesions and a patient with cutaneous melanoma who achieved an 81% reduction in tumor volume. These signals of anti-cancer activity indicate that NUC-3373, in addition to being a targeted TS

inhibitor, may promote an anti-tumor immune response and potentiate the activity of immune checkpoint inhibitors.
 In 2025, we expect to announce data from the NuTide:303 trial of NUC-3373 in combination with pembrolizumab in patients with solid tumors.
 •Leverage our proprietary ProTide technology platform to develop additional product candidates. 
 
We are pursuing the transformation of both widely used nucleoside analogs and novel nucleoside analogs, which we believe have the potential to address additional areas of unmet medical need in oncology.
•Continue to protect and strengthen our intellectual property position. 
 
We own or have exclusive rights to the core technologies underlying our ProTide technology platform. We have been granted patents in key markets, including the United States, Europe, China and Japan, protecting the composition of matter of NUC-7738, NUC-3373 and other of our product candidates. We intend to further expand and enhance our intellectual property position. We are actively evaluating new intellectual property opportunities as they arise, with the intention of further expanding our intellectual property position and defending our patents when necessary.
 •Build a focused commercial organization. 
 
We have worldwide rights to all product candidates that we are developing. We believe that the healthcare professionals who treat the majority of patients with the cancers we are initially targeting with our ProTides can be addressed by a relatively focused sales and marketing team. We currently plan to commercialize any product candidates for which we receive regulatory marketing approval using a specialized sales force, either independently or in partnership with a commercialization partner, in the United States and Europe.
 

Our Pipeline

 We take a scientifically driven approach to designing ProTides, which we believe have the potential to result in highly efficacious cancer therapies with improved tolerability. Our pipeline of product candidates in clinical development and their current development stage is summarized below.
<{self.tag} alt="{self.alt}" src="{self